Comparing TrimRx vs MEDVi comes down largely to cost and plan structure. MEDVi rewards longer commitments with lower displayed rates, while TrimRx combines competitive month-to-month pricing with locked-in price protection. We compared TrimRx cost, MEDVi cost, semaglutide prices, tirzepatide prices, and estimated 12-month totals so you can see which structure fits you.
Both are strong choices—but for different buyers.
From $116/mowith the displayed long-term semaglutide option
No obligation to see whether treatment is appropriate.
From $149/mowith the displayed long-term semaglutide option
See available plans before choosing a commitment.
Compare pricing, plan lengths, medication options, and the key differences between TrimRx and MEDVi.
| Comparison | MEDVi | TrimRx |
|---|---|---|
| Best for | Lower equivalent rates with longer plans | Flexible plan lengths and locked pricing |
| Semaglutide | Displayed from $116/mo on the longest option | Displayed from $149/mo on the longest option |
| Tirzepatide | Displayed from $166/mo on the longest option | Displayed from $249/mo on the longest option |
| Plan lengths shown | 4, 12, 24 and 48 weeks | Monthly, 3, 6 and 12 months |
| Offer emphasis | Flash savings and lower long-term rates | Price Locked Forever |
| Installments | Easy 0% installments shown on longer plans | 0% financing options shown |
| Medical process | Online intake and provider review | Online intake and provider review |
| Prescription required | Yes, if medically appropriate | Yes, if medically appropriate |
Rates are the providers’ displayed monthly equivalents as reviewed September 1, 2026. Long-term plans may involve a larger commitment, shipment schedule, financing approval, and other terms. Medication is prescribed only when clinically appropriate.
MEDVi has the lower displayed long-plan total; TrimRx offers the stronger price-lock and month-to-month proposition.
Displayed longest-plan monthly rate × 12
Displayed longest-plan monthly rate × 12
These are simple price comparisons, not guaranteed checkout totals. They exclude any medical changes, add-ons, taxes, or revised offers and do not account for whether a patient continues treatment for a full year.
A low “per month” figure can represent a longer supply commitment rather than a simple month-to-month subscription. That distinction matters here. Both providers lower the equivalent monthly rate as the plan gets longer, but they market the value differently.
MEDVi leads with flash savings. Its displayed rates drop most sharply on 24- and 48-week supplies. TrimRx leads with locked pricing. Its long-term value proposition is knowing the selected rate will not climb later, according to the offer language.
If your only question is “Which costs less over a year?”, MEDVi wins the current math. If your concern is “Will my price remain predictable if I continue?”, TrimRx makes the more direct promise.
For semaglutide, MEDVi currently displays a 4-week rate of $199 per month, with a lower first-month flash offer shown during our review. Longer options display equivalent rates down to $116 per month. TrimRx displays $174 monthly, falling to $149 per month with its 12-month plan.
That creates an interesting split: TrimRx has the lower standard short-term monthly figure ($174 vs. $199), while MEDVi has the lower long-term figure ($116 vs. $149). Buyers who are unsure about a long commitment may therefore view TrimRx’s shorter plan more favorably, even though MEDVi wins the annual calculation.
| Provider | Plan | Displayed rate | Supply total | Advertised savings |
|---|---|---|---|---|
| MEDVi | 4 weeks | $199/mo | $199 | $100 flash savings$99 first month displayed |
| 12 weeks | $133/mo | $399 | $198 | |
| 24 weeks | $124/mo | $744 | $445 | |
| 48 weeks | $116/mo | $1,392 | $989 | |
| TrimRx | Monthly | $174/mo | $174 | Price locked |
| 3 months | $166/mo | $498 | $23 vs. monthly | |
| 6 months | $158/mo | $948 | $95 vs. monthly | |
| 12 months | $149/mo | $1,788 | $289 vs. monthly |
Supply totals are the displayed monthly equivalent multiplied by the stated plan length. Provider-advertised savings can use different reference prices and rounding, so they may not equal the simple difference shown by monthly-rate multiplication.
Compare MEDVi’s long-plan savings with TrimRx’s flexible, locked-price offer—then confirm the live terms and your eligibility.
MEDVi’s displayed tirzepatide pricing starts at $299 for a 4-week supply and reaches an equivalent $166 per month on the 48-week option. TrimRx displays $279 month to month and $249 per month on its 12-month option.
The same short-term/long-term pattern appears again: TrimRx’s monthly option starts lower, while MEDVi’s longest option creates the much lower estimated annual total. MEDVi’s estimated advantage is $996 over 12 months using the displayed longest-plan rates.
| Provider | Plan | Displayed rate | Supply total | Advertised savings |
|---|---|---|---|---|
| MEDVi | 4 weeks | $299/mo | $299 | $100 flash savings$199 first month displayed |
| 12 weeks | $193/mo | $579 | $308 | |
| 24 weeks | $183/mo | $1,098 | $695 | |
| 48 weeks | $166/mo | $1,992 | $2,489 | |
| TrimRx | Monthly | $279/mo | $279 | Price locked |
| 3 months | $266/mo | $798 | $38 vs. monthly | |
| 6 months | $258/mo | $1,548 | $125 vs. monthly | |
| 12 months | $249/mo | $2,988 | $349 vs. monthly |
Rates and advertised savings were captured from the provider plan selectors. Confirm the live checkout price, financing terms, shipment schedule, and cancellation policy before enrolling.
MEDVi is the stronger fit if you have already decided that a longer treatment plan fits your budget and medical plan, and your main priority is reducing the equivalent monthly cost.
Potential drawback: the most attractive monthly equivalents are tied to longer supply choices. Review payment and shipment terms before committing.
TrimRx is the stronger fit if predictability matters more than squeezing out the absolute lowest annual number. The provider’s Price Locked Forever positioning is easy to understand, and the displayed plan ladder gives buyers several commitment levels.
Tradeoff to consider: TrimRx’s longest displayed rates are higher, but its lower month-to-month entry prices and locked-rate promise may be more valuable if flexibility and predictability matter to you.
Neither service guarantees approval, a particular medication, or weight-loss results. Semaglutide and tirzepatide are prescription treatments and are not appropriate for everyone.
MEDVi is the better fit for long-term deal seekers. Its displayed 48-week rates produce the lower estimated annual total for semaglutide and tirzepatide. If you already expect to stay with treatment and are comfortable reviewing a longer commitment, MEDVi’s savings are meaningful.
TrimRx is the better fit for flexibility and confidence in future pricing. It starts with lower standard month-to-month rates for both medications, offers four commitment levels, and makes Price Locked Forever central to its offer. For many buyers, that combination can matter more than the lowest theoretical annual total.
The right move is to check eligibility and live plan terms with the provider matching your priority. A clinical decision should come before a price decision.
MEDVi costs less when comparing the displayed longest-plan rates. Its estimated 12-month totals are $1,392 for semaglutide and $1,992 for tirzepatide, versus $1,788 and $2,988 with TrimRx. Actual checkout terms can change.
MEDVi displays tirzepatide at $299 per month for 4 weeks, $193 per month for 12 weeks, $183 per month for 24 weeks, and an equivalent $166 per month for 48 weeks. Longer options are shown with 0% installment availability, subject to terms.
MEDVi semaglutide costs $199, $133, $124, or $116 per month depending on whether the displayed supply covers 4, 12, 24, or 48 weeks. MEDVi tirzepatide costs $299, $193, $183, or $166 per month across those same plan lengths.
The MEDVi price list includes semaglutide and tirzepatide across 4-, 12-, 24-, and 48-week supplies. Longer plans display lower equivalent monthly rates, while eligible longer options advertise 0% installments. Review the complete tables above for supply totals and advertised savings.
TrimRx displays semaglutide from $174 month to month or $149 per month with the longest option. Tirzepatide is displayed from $279 month to month or $249 per month with the longest option.
TrimRx currently displays the lower month-to-month rate: $174 vs. $199 for semaglutide and $279 vs. $299 for tirzepatide. MEDVi becomes less expensive on the longest options.
Yes, the offers reviewed for this comparison showed both semaglutide and tirzepatide pathways. The medication prescribed depends on clinical evaluation, eligibility, and availability.
Yes. Both are telehealth services, and either treatment pathway requires an online medical evaluation and a prescription from a licensed provider when clinically appropriate.
Both offers present an online medical process and home delivery, with free shipping described. Confirm exactly what is included on the live checkout page before purchasing.
These offers are presented as cash-pay telehealth programs. Coverage and HSA/FSA eligibility can vary, so confirm directly with the provider and your plan administrator.
Potentially, but do not overlap or change prescription treatment on your own. Speak with a licensed provider, disclose your current medication and dose, and review any cancellation or unused-supply terms.
MEDVi is built around stronger long-plan savings. TrimRx pairs competitive entry pricing with flexible plan lengths and a clear price-lock promise.
Price research reviewed September 5, 2026.